TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CEFTRIAXONE

CEFTRIAXONE SODIUM
Infectious Disease Approved 2003-09-30
26
Indications
--
Phase 3 Trials
22
Years on Market

CEFTRIAXONE Approval History

Loading approval history...

What CEFTRIAXONE Treats

2 indications

CEFTRIAXONE is approved for 2 conditions since its original approval in 2003. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Lower Respiratory Tract Infection
  • Acute Bacterial Otitis Media
Source: FDA Label

Drugs Similar to CEFTRIAXONE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMOXICILLIN PEDIATRIC
AMOXICILLIN
2 shared
Teva
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
AUGMENTIN '125'
AMOXICILLIN
2 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
AUGMENTIN '250'
AMOXICILLIN
2 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
AUGMENTIN '875'
AMOXICILLIN
2 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
AUGMENTIN XR
AMOXICILLIN
2 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
CEFTRIAXONE SODIUM
2 shared
B BRAUN
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
CEFTRIAXONE IN PLASTIC CONTAINER
CEFTRIAXONE SODIUM
2 shared
Baxter
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM
2 shared
ANDA REPOSITORY
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)
AMOXICILLIN
2 shared
Novartis
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
LAROTID
AMOXICILLIN
2 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
VOQUEZNA TRIPLE PAK
AMOXICILLIN
2 shared
PHATHOM
Shared indications:
Lower Respiratory Tract InfectionAcute Bacterial Otitis Media
ACHROMYCIN V
TETRACYCLINE HYDROCHLORIDE
1 shared
AVET
Shared indications:
Lower Respiratory Tract Infection
AZACTAM
AZTREONAM
1 shared
Bristol-Myers Squibb
Shared indications:
Lower Respiratory Tract Infection
AZTREONAM
AZTREONAM
1 shared
Pfizer
Shared indications:
Lower Respiratory Tract Infection
CEFOTAN
CEFOTETAN DISODIUM
1 shared
PAI HOLDINGS PHARM
Shared indications:
Lower Respiratory Tract Infection
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
CEFOXITIN SODIUM
1 shared
B BRAUN
Shared indications:
Lower Respiratory Tract Infection
CEFOXITIN IN PLASTIC CONTAINER
CEFOXITIN SODIUM
1 shared
SAMSON MEDCL
Shared indications:
Lower Respiratory Tract Infection
CEFUROXIME
CEFUROXIME
1 shared
Hikma
Shared indications:
Lower Respiratory Tract Infection
ERY-TAB
ERYTHROMYCIN
1 shared
PHARMOBEDIENT
Shared indications:
Lower Respiratory Tract Infection
ERYTHROCIN
ERYTHROMYCIN LACTOBIONATE
1 shared
Pfizer
Shared indications:
Lower Respiratory Tract Infection
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFTRIAXONE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cult...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.